Bloomberg the Company

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Follow Us

Industry Products

Markets & Finance

CIBC Repeats Underperform on Chiron


Chiron (CHIR) reported strong Q3 EPS but lowered growth estimates. CIBC reiterated its underperform rating on the shares.

Analyst Matt Geller says Chiron's $0.46 Q3 EPS resulted from strong sales of flu vaccines, but growth prospects remain weak. He says the company will discontinue 3 development projects: SILCAAT, an HIV treatment; HBV-MF59, an immunotherapy treatment for chronic HBV; and its PA-1806 program for treatment of infections tied to cystic fibrosis. Geller notes that Chiron lowered its 25% 200304 average annual growth rate estimate to 20%. He raised his $1.15 2002 EPS estimate to $1.19 to account for the strong Q3, but leaves his $1.44 2003 forecast unchanged.


LIMITED-TIME OFFER SUBSCRIBE NOW
 
blog comments powered by Disqus